Clinical Trials Browser

Phase 2 × Breast Neoplasms × Nivolumab × Clear all

NCT03789110 2026-02-06

NIMBUS: Nivolumab Plus Ipilimumab in Metastatic Hypermutated HER2-negative Breast Cancer

Phase 2 Active not recruiting

30 enrolled 15 charts

Breast Neoplasms

NCT03546686 2025-10-27

Peri-Operative Immune Checkpoint Inhibition and Cryoablation in Women With Triple-negative Breast Cancer

Phase 2 Recruiting

Breast Neoplasms

NCT03414684 2025-09-29

Carboplatin +/- Nivolumab in Metastatic Triple Negative Breast Cancer

Phase 2 Active not recruiting

78 enrolled 46 charts

Breast Neoplasms

NCT03650894 2025-03-10

Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer Patients

Phase 2 Active not recruiting

Breast Neoplasms

NCT03409198 2024-10-15

ICON

Phase 2 Completed

Breast Neoplasms, Neoplasms

NCT03815890 2024-05-30

BELLINI

Phase 2 Recruiting

Breast Neoplasms

NCT03818685 2024-02-12

BreastImmune03

Phase 2 Unknown

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04591431 2023-10-03

ROME

Phase 2 Unknown

BreastGastrointestinalThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms

NCT05429866 2023-03-08

Immunological Variables Associated to ICI Toxicity in Cancer Patients

Phase 2 Unknown

BreastDermatologicGastrointestinalGenitourinaryHead & NeckOther solid neoplasmThoracic

Mesothelioma, Malignant, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Melanoma, Carcinoma, Merkel Cell, Small Cell Lung Carcinoma

NCT02499367 2022-03-22

TONIC

Phase 2 Unknown

Breast Neoplasms, Neoplasm Metastasis

NCT04159818 2022-03-22

TONIC-2

Phase 2 Recruiting

Breast Neoplasms, Neoplasm Metastasis

NCT03952325 2021-07-30

CONTESSA TRIO

Phase 2 Terminated

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT04659551 2020-12-09

GIADA

Phase 2 Completed

Breast Neoplasms

NCT02892734 2020-07-16

Ipilimumab and Nivolumab in Treating Patients With Recurrent Stage IV HER2 Negative Inflammatory Breast Cancer

Phase 2 Terminated

3 enrolled 11 charts

Breast Neoplasms, Inflammatory Breast Neoplasms